Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
$6.76
$6.76
$2.06
$7.01
$946.72M1.598.44 million shsN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.75
+2.9%
$1.74
$1.41
$5.01
$9.68M1.1926,136 shs9,119 shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$27.86
+1.5%
$27.49
$17.82
$30.69
$2.03B0.05551,956 shs558,076 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$65.78
-1.7%
$62.86
$40.61
$69.89
$4.18B2.26555,878 shs628,374 shs
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$11.49
-0.6%
$10.43
$5.35
$16.15
$627.08M1.14672,891 shs185,804 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.00%0.00%0.00%+754.41%+754.41%
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
0.00%+4.48%0.00%+10.06%-54.90%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
0.00%-0.66%-7.86%+37.35%+43.88%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%+4.85%-3.43%+19.68%+55.57%
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
0.00%-1.25%+3.10%+91.10%-12.46%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.5158 of 5 stars
3.54.00.00.00.00.81.3
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.2836 of 5 stars
3.54.00.00.01.43.30.6
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.8115 of 5 stars
3.52.00.04.31.40.80.6
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
4.028 of 5 stars
3.60.00.04.82.40.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.00
N/AN/AN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
3.00
Buy$15.50785.71% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$38.8039.29% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.00
Buy$78.0718.69% Upside
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
3.29
Buy$23.20102.00% Upside

Current Analyst Ratings Breakdown

Latest RYTM, APRE, KNSA, ACHN, and STOK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$88.00
7/1/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/26/2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$11.00
6/26/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$84.00
5/29/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$78.00 ➝ $94.00
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/14/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$47.00 ➝ $35.00
5/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$66.00 ➝ $72.00
4/29/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $45.00
4/16/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
4/9/2025
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/A$1.92 per shareN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$1.50M6.45N/AN/A$3.55 per share0.49
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$423.24M4.80N/AN/A$6.60 per share4.22
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$130.13M32.16N/AN/A$0.35 per share187.93
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
$36.56M17.15N/AN/A$4.32 per share2.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
-$70.27M-$0.51N/AN/AN/AN/A-30.95%-29.09%N/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.96M-$2.37N/AN/AN/A-1,095.02%-68.39%-55.74%8/11/2025 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M-$0.25N/A111.42N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$260.60M-$2.81N/AN/AN/A-123.26%-739.62%-44.27%8/5/2025 (Estimated)
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
-$88.98M$0.7914.54N/AN/A26.33%19.08%15.72%8/5/2025 (Estimated)

Latest RYTM, APRE, KNSA, ACHN, and STOK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/22/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.08N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.6543-$0.66-$0.0057-$0.66N/A$0.16 million
5/7/2025Q1 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.69-$0.81-$0.12-$0.81$40.43 million$37.72 million
4/29/2025Q1 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.02$0.11+$0.09$0.11$128.35 million$137.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
N/AN/AN/AN/AN/A
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
0.01
8.96
8.96
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
5.90
5.90
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.66
3.43
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
3.30
3.13
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
N/A
8.41
8.41
CompanyEmployeesShares OutstandingFree FloatOptionable
Achillion Pharmaceuticals, Inc. stock logo
ACHN
Achillion Pharmaceuticals
56140.05 millionN/AOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
75.53 million4.78 millionNo Data
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22072.97 million33.95 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14063.62 million59.74 millionOptionable
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
10054.60 million49.41 millionOptionable

Recent News About These Companies

DONE DEAL: Stoke snap up Man City striker Mubama
Mubama set for Stoke loan switch
STOK Stoke Therapeutics, Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Achillion Pharmaceuticals stock logo

Achillion Pharmaceuticals NASDAQ:ACHN

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$1.75 +0.05 (+2.94%)
Closing price 07/3/2025 01:56 PM Eastern
Extended Trading
$1.75 0.00 (0.00%)
As of 08:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$27.86 +0.42 (+1.51%)
Closing price 07/3/2025 02:30 PM Eastern
Extended Trading
$27.86 0.00 (0.00%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$65.78 -1.15 (-1.71%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$65.74 -0.04 (-0.06%)
As of 06:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stoke Therapeutics stock logo

Stoke Therapeutics NASDAQ:STOK

$11.48 -0.07 (-0.56%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$11.48 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.